Clinical Study
Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center
| | Group 1 | Group 2 | value |
| Primary surgery: | 80.8% (42/52) | 75.2% (82/109) | 0.549 | (i) macroscopically radical | 19.0% (8/42) | 56.1% (46/82) | 0.000 | (ii) not macroscopically radical | 81.0% (34/42) | 43.9% (36/82) | | Interferon | 65.4% (34/52) | 42.2% (46/109) | 0.007 | Somatostatin analogues | 73.1% (38/52) | 66.1% (72/109) | 0.470 | Radionuclide treatment | 9.6% (5/52) | 13.8% (15/109) | 0.610 | Radiofrequency ablation (RFA) | 1.9% (1/52) | 15.6% (17/109) | 0.008 | Systemic chemotherapy | 5.8% (3/52) | 4.6% (5/109) | 0.710 | Temozolomide | 1.9% (1/52) | 1.8% (2/109) | 1.000 | Embolisation | 0.0% (0/52) | 8.3% (9/109) | 0.030 | New surgery: | | | | (i) none | 100% (52/52) | 89.9% (98/109) | 0.000 | (ii) small bowel resection | 0.0% (0/52) | 3.7% (4/109) | | (iii) lymph node resection | 0.0% (0/52) | 0.9% (1/109) | | (iv) liver resection | 0.0% (0/52) | 4.6% (5/109) | | (v) bone resection | 0.0% (0/52) | 0.9% (1/109) | |
| New surgery in total | 0.0% | 10.1% | |
|
|